NIH AMP SCZ DPACC U24 eligibility Guide
Updated 8 official sources
Quick Answer: NIH AMP SCZ DPACC U24 eligibility is not broad: according to Simpler.Grants.gov, only Brigham and Women's Hospital may apply.
Full answer and how we checked it
Everyone else needs 4 facts from it: this is single-source, $5,000,000, clinical trial not allowed, and focused on data processing, analysis, and coordination for AMP SCZ. The 2026 decision turns on 7 checks.
Who this is for: Research offices, schizophrenia investigators, data-science teams, NIMH portfolio watchers, and business-development teams who need to know whether the AMP SCZ DPACC U24 is open to them or only useful as a partnership and market signal.
Data note: This guide uses the NIH AMP SCZ DPACC U24 opportunity (opens in a new tab), NIMH AMP SCZ program context (opens in a new tab), the NIMH Data Archive AMP SCZ collection (opens in a new tab), the live AMP SCZ DPACC program page, and Grantsights award-data signals checked again on June 2, 2026. On October 9, 2026, Grantsights rechecked the Grants.gov listing for RFA-MH-27-205 (opens in a new tab), the full announcement attached to it, and NIH RePORTER (opens in a new tab) records for the current DPACC award.
In this guide
- June 2026 Source Check
- NIH AMP SCZ DPACC U24 Eligibility: 3 Stop Signals
- Funding, Timing, and Award Math: $5M, 1 Award, June 9, 2026
- What the Full Announcement Adds: 3-Year Cap, No Budget Limit, December 2026 Start
- The Current DPACC Award in NIH RePORTER
- AMP SCZ DPACC vs R01, R21, U24, and Data-Use Paths
- What NIH Doesn't Tell You
- 5 Real-World AMP SCZ Scenarios
- 7 Draft Checks to Run First
- 7 Route Checks for RFA-MH-27-205
- Sources
Quick Facts
- Agency
- HHS
- Last deadline
- Jun 9, 2026 (passed)
- Status
- Closed
Assistance Listing 93.242: all awards
Source: USASpending.gov FY2024These figures cover all National Institutes of Health awards under Assistance Listing 93.242, of every award type. They are not figures for the award this guide describes, and one award of that kind can be far smaller.
- Total Awards (FY2024, whole listing)
- 6,220
- Avg Award (whole listing)
- $2,481,843
- Median Award (whole listing)
- $1,562,432
- Total Funding (FY2024, whole listing)
- $1.8B
- YoY Funding Trend
- -0.5%
Data last verified: May 18, 2026
According to Simpler.Grants.gov (opens in a new tab), RFA-MH-27-205 is a single-source NOFO, and only Brigham and Women's Hospital may apply. That means most searchers do not need encouragement. They need a fast stop signal and a better next step.
Use this guide with the live AMP SCZ DPACC program page, then compare it with NIH grants complete guide, NIH R01, R21, R03, and K awards, how grant reviewers score applications, what is a NOFO, and how to write a federal grant proposal. The answer for nearly every reader is "you can't apply," so this guide says it first.
June 2026 Source Check
Simpler.Grants.gov listed RFA-MH-27-205, posted May 7, 2026; the window closed June 9, 2026, with 1 expected award, $5,000,000 in program funding, no cost sharing, and only Brigham and Women's Hospital as the eligible applicant.
| Source fact | What it means |
|---|---|
| Single-source applicant | Most readers should not draft an application. |
| Closing date | June 9, 2026 has closed; check the current notice for the next closing date before treating any internal timeline as active. |
| Funding signal | $5,000,000 is useful market context, not broad competition evidence. |
| Clinical trial status | The U24 is clinical trial not allowed. |
| Data role | The work is data processing, analysis, and coordination for AMP SCZ. |
| Better paths | Other teams should compare R01, R21, data-use, collaboration, SBIR/STTR, or future NIMH routes. |
A university schizophrenia lab, data vendor, or biomarker startup can still use the page as a portfolio signal, but the next click should be NIH grants complete guide, NIH mechanism comparison, or the live AMP SCZ DPACC program page, not an application package.
NIH AMP SCZ DPACC U24 Eligibility: 3 Stop Signals
3 stop signals come before any writing plan. First, only Brigham and Women's Hospital may apply. Second, non-U.S. entities are not eligible, non-U.S. components of U.S. organizations are not eligible, and foreign components are not allowed. Third, the opportunity is clinical trial not allowed.
| Stop signal | What it means | Action for most readers |
|---|---|---|
| Single-source applicant | Only Brigham and Women's Hospital may apply | Do not write an application |
| Clinical trial not allowed | This is not an intervention trial route | Look for trial NOFOs elsewhere |
| DPACC role | Data processing, analysis, and coordination are the work | Look for collaboration or data-use paths |
The common mistake is treating the presence of a live grant page as proof that any qualified schizophrenia data team can apply. They can't. This is a single-source continuation award for a named role, and the notice lists Renewal as the application type for Brigham and Women's Hospital.
Funding, Timing, and Award Math: $5M, 1 Award, June 9, 2026
$5,000,000 is listed as program funding, 1 expected award, and the award maximum. According to Simpler.Grants.gov, the closing date was June 9, 2026, the posted date was May 7, 2026, cost sharing was not required, and the instrument type was a cooperative agreement.
| Fact | Source-backed read |
|---|---|
| Opportunity number | RFA-MH-27-205 |
| Posted date | May 7, 2026 |
| Closing date | June 9, 2026 (passed) |
| Program funding | $5,000,000 |
| Expected awards | 1 |
| Award maximum | $5,000,000 |
According to USAspending.gov (opens in a new tab) data, assistance listing 93.242 had about $1.77B in FY2024 obligations across 6,220 awards active that year. Those family numbers show large NIMH-adjacent research activity, but they should not be used to imply broad eligibility for this specific NOFO.
What the Full Announcement Adds: 3-Year Cap, No Budget Limit, December 2026 Start
The $5,000,000 figure comes from the Grants.gov synopsis, but the full announcement attached to the Grants.gov listing (opens in a new tab) says application budgets aren't limited and must reflect the project's actual needs. The maximum project period is 3 years. The earliest submission date was May 9, 2026, the due date was June 9, 2026 at 5:00 PM local time, late applications weren't accepted, and the NOFO expired June 10, 2026. Grants.gov set the listing to archive on August 8, 2026.
| Step in the notice | Date or rule |
|---|---|
| Application types allowed | New, Renewal, Resubmission (Renewal named for Brigham and Women's Hospital) |
| Scientific merit review | July 2026 |
| National Advisory Mental Health Council | October 2026 |
| Earliest start date | December 2026 |
| Data Management and Sharing Plan | Required, on the NIH DMS Plan format page (NIH recommends 2 pages) |
| NIMH Data Archive | Budget for submitting common data elements to NDA |
| Steering Committee | DPACC chairs it at least once every 2 weeks; budget travel for an annual in-person meeting |
The notice explains why the award exists now. According to the full announcement, the AMP SCZ longitudinal study met its recruitment targets with more than 2,600 participants at clinical high risk, each followed for up to 24 months with clinical, cognitive, neurophysiology, neuroimaging, genetics, fluid biomarker, speech, facial expression, and digital measures. NIMH projects the full dataset won't be complete until June 2027, so this award keeps the processing pipeline, curation through the 24-month time points, and the primary analyses running.
How reviewers score the DPACC application
Peer review still applies to a single-source NOFO. The announcement says a non-meritorious application won't be funded, and reconsideration requests aren't accepted. Reviewers score these criteria separately:
- Significance: whether the DPACC meets the needs of the research project it serves and whether its scope fits those needs.
- Investigators: whether the PD/PIs have a record of managing multicenter collaborative research and coordinating clinical research, plus governance and conflict-resolution plans if there are multiple PIs.
- Approach: the operational plan, organizational structure, benchmarks for success, workflow, and timeline, plus attention to biological variables such as sex.
- Environment: institutional support and resources for electronic information handling.
Because the application is a renewal, the notice says reviewers will also weigh progress made in the last funding period. After review, funding turns on merit, available funds, and NIMH program priorities.
The Current DPACC Award in NIH RePORTER
Grantsights pulled NIH RePORTER on October 9, 2026. The existing DPACC is project U24MH124629 (opens in a new tab), titled Psychosis Risk Evaluation, Data Integration and Computational Technologies (PREDICT), at Brigham and Women's Hospital with Martha E. Shenton as contact PI. It began September 9, 2020 under RFA-MH-20-341. The FY2026 record (4U24MH124629-06) is a non-competing extension noticed May 18, 2026, with $5,221,430 in total costs ($4,236,482 direct) for June 1, 2026 through May 31, 2027.
The same hospital also holds a separate award, U24MH137171 (opens in a new tab), for the Clinical Trial DPACC under RFA-MH-24-151, with $7,083,201 in FY2026 and a project end date of May 31, 2029. Don't confuse the two. RFA-MH-27-205 concerns the longitudinal-study DPACC, not the clinical trial coordinating center. A related AMP SCZ clinical trial network award to Yale University, U01MH137298 (opens in a new tab) (ProCAN), shows $17,070,000 in FY2026.
AMP SCZ DPACC vs R01, R21, U24, and Data-Use Paths
5 nearby paths matter for users who cannot apply. The right next step is not to force a single-source application. It is to redirect the researcher to a route that matches their real role.
| Reader situation | Better path | Why |
|---|---|---|
| Named DPACC applicant | AMP SCZ DPACC U24 | Single-source eligibility matches |
| External schizophrenia data scientist | R01, R21, or data-use collaboration | Own research question may fit elsewhere |
| Clinical trial team | NIMH clinical-trial NOFO | U24 is trial not allowed |
| Industry biomarker partner | Partnership or contract path | Grant eligibility may not fit |
| Research office tracking market signals | Save program page and monitor NIMH | Useful for timing and portfolio context |
For NIMH route choice, start with NIH grants complete guide and NIH R01, R21, R03, and K awards. If the team is still reading NOFOs loosely, what is a NOFO can prevent wasted work.
What NIH Doesn't Tell You
4 things remain unclear if a user only reads the listing. NIH says who can apply and what the DPACC does. It does not tell everyone else how to use the page.
First, NIH doesn't tell a non-eligible reader to stop in plain language. The eligibility text is there, but many users skim for deadline and dollar amount.
Second, NIH doesn't package the partnership signal. According to NIMH, AMP SCZ is built around clinical high-risk data, biomarker work, and shared analysis goals. A team that cannot apply may still have a future collaboration, methods, or data-use path.
Third, NIH doesn't compare DPACC with a normal R01. If you have an independent schizophrenia data question, you probably need a research-project route, not this U24.
Fourth, NIH doesn't explain the reputational risk of applying when the NOFO says only a named applicant is eligible. Don't spend institutional time on an application that the eligibility section already rules out.
5 Real-World AMP SCZ Scenarios
5 scenarios show what readers should do. The June 9, 2026 deadline has passed, so the only live question for Brigham and Women's Hospital is the July 2026 review and October 2026 council outcome. A university lab with a machine-learning schizophrenia project shouldn't draft a U24 application. It should look for an R01, R21, partnership, or data-access route.
| Scenario | Best action | Reason |
|---|---|---|
| Brigham DPACC team | Track review and council outcome | Applicant rule matches; deadline passed |
| External university data lab | Seek R01/R21 or collaboration | Not eligible for this NOFO |
| Clinical high-risk cohort site | Explore partnership signals | May connect to AMP SCZ work |
| Digital biomarker startup | Look for contracts, SBIR/STTR, or partners | Company role may be indirect |
| Sponsored research office | Flag as no-apply for most PIs | Saves time |
For example, a PI with a psychosis prediction model who wants AMP SCZ data shouldn't chase the U24. The notice says DPACC uploads data with Globally Unique Identifiers to the NIMH Data Archive, so the realistic route is an NDA data-access request paired with an R01 or R21 that asks the PI's own question.
7 Draft Checks to Run First
7 checks only matter if the reader is the eligible applicant or supporting that team. Otherwise, stop after check 1.
- The applicant is Brigham and Women's Hospital.
- The application does not propose a clinical trial.
- The work centers on data processing, analysis, and coordination.
- The plan shows continuity from existing AMP SCZ networks.
- Data sharing and governance are clear.
- Staffing covers biomarker, clinical, analytic, and coordination tasks.
- The budget matches a $5,000,000 single award.
According to Simpler.Grants.gov, this NOFO listed $5,000,000, 1 expected award, and a June 9, 2026 closing date that has already passed. Grantsights analysis of USAspending.gov (opens in a new tab) FY2024 records puts the connected assistance listing, 93.242 Mental Health Research Grants, at about $1.77B in obligations across 6,220 awards active that year. That big number describes NIMH's whole research-grant listing, while the eligibility rule here admits one hospital.
7 Route Checks for RFA-MH-27-205
Checked against Simpler.Grants.gov (opens in a new tab), the NIMH AMP SCZ page (opens in a new tab), the NDA AMP SCZ collection (opens in a new tab), and the Grants.gov listing (opens in a new tab) on May 26, 2026, and rechecked on October 9, 2026.
| Check | What the source says | What to do |
|---|---|---|
| Eligibility | Brigham and Women's Hospital only; no foreign organizations or foreign components | Stop here unless you're on that team |
| Status | Due June 9, 2026; NOFO expired June 10, 2026 | Don't plan a submission |
| Budget | Not limited in the full announcement; $5,000,000 ceiling on the synopsis | Read the full announcement, not just the synopsis |
| Project period | Up to 3 years | Expect DPACC work to run past the June 2027 dataset completion |
| Review | Significance, Investigators, Approach, Environment, plus renewal progress | No reconsideration requests |
| Data | DMS Plan (NIH recommends 2 pages); NDA uploads with GUIDs | Outside teams should plan NDA access requests |
| Next action | Council review October 2026; earliest start December 2026 | Watch RePORTER for the award record |
Final public checklist
- Confirm whether U24 is the right route or whether a nearby program fits better.
- If you want AMP SCZ data, check the NDA collection's access rules instead of this NOFO.
Sources
- NIH AMP SCZ DPACC U24 opportunity: Simpler.Grants.gov (opens in a new tab)
- NIMH AMP SCZ program context: nimh.nih.gov (opens in a new tab)
- NIMH Data Archive AMP SCZ collection: nda.nih.gov (opens in a new tab)
- Grantsights AMP SCZ DPACC program page: AMP SCZ DPACC U24
Largest awards active in FY2024
One row per recipient, its largest award | 6,220 Assistance Listing records | Avg: $2.5M
The Johns Hopkins University
MD
Rutgers, the State University
NJ
Use the visible recipient rows as free source context
This program has no reviewed paid report today.
No reviewed paid report is currently offered for this program. The visible source rows remain free.
Next steps
Where to go next
These next pages help you move from research into a specific grant choice.
Open the program record
Confirm the single-source applicant rule, $5M award signal, June 9 2026 close, and no-trial status.
NIH route context
Use when the reader is not the named applicant and needs a usable NIMH path.
Compare NIH mechanisms
Redirect data scientists toward R01, R21, collaboration, data-use, or SBIR/STTR paths.
Find grants that fit you
Free eligibility check: answer 9 questions and see ranked matches with deadlines and fit reasons.
Frequently Asked Questions
Who is eligible for the NIH AMP SCZ DPACC U24?
The Simpler.Grants.gov listing says only Brigham and Women's Hospital may apply for this single-source NOFO.
How much funding is listed for AMP SCZ DPACC U24?
Simpler.Grants.gov lists $5,000,000 in program funding, 1 expected award, and a $5,000,000 award maximum.
When does AMP SCZ DPACC U24 close?
Simpler.Grants.gov listed a closing date of June 9, 2026, which has passed; check Simpler.Grants.gov for a reissued listing of this NOFO.
Does AMP SCZ DPACC U24 allow clinical trials?
No. RFA-MH-27-205 is listed as U24 Clinical Trial Not Allowed.
Who should read this if they cannot apply?
Most teams should use it as a market and partnership signal, then look for AMP SCZ data access, collaboration, schizophrenia R01/R21 routes, or NIMH data-analysis opportunities.
Last updated October 13, 2026. Corrected October 13, 2026: what changed. Published by Grantsights from public sources. See our editorial policy, how we build and check guides, corrections and how we make money.
Related Guides
PAR-25-338 academic industrial R01 eligibility Guide
PAR 25 338 academic industrial guide: 7 checks for eligibility, source status, budget, evidence, route fit, and review criteria in 2026.
NIH ALS Expanded Access U01 Eligibility
NIH ALS expanded access U01 guide for RFA-NS-26-001, trial-site eligibility, small-business IND sponsor rules, and route fit.
Animal Biological Material Resource Centers P40 Guide
Animal and Biological Material guide: 7 checks for eligibility, source status, budget, evidence, route fit, and review criteria in 2026.